Morningside Pharmaceuticals Limited
Registered name: MORNINGSIDE PHARMACEUTICALS LIMITED
Morningside Pharmaceuticals Limited made £75.3m revenue and £13.4m profit in the year to 31 Dec 2025. read from filing text
Morningside Pharmaceuticals Limited’s revenue fell 10% to £75.3m in the year to 31 Dec 2025, with £13.4m profit and 47 employees. The company is classified under “manufacture of pharmaceutical preparations” and is based in Northampton; we hold 4 years of its filed accounts.
- Status
- Active
- Location
- Northampton, East Midlands
- Age
- 34 yrs · since 1991
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “The company is wholly owned by Aspire Bidco Limited, a company registered in Jersey. The smallest company within which the accounts are consolidated is Aspire Topco Limited, a company registered in Je”
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2022 | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|---|---|---|---|---|
| Disclosure | Full P&Lread from filing text | Full P&Lread from filing text | Full P&Lread from filing text | Full P&Lread from filing text |
| Profit & loss | ||||
| Revenue (turnover) | £82.1m | £79.4m | £84m | £75.3m |
| Cost of sales | £56.8m | £57.1m | £59.3m | £54.5m |
| Gross profit | £25.3m | £22.3m | £24.7m | £20.8m |
| Operating profit | £14m | £14.4m | £17.3m | £13.7m |
| Profit before tax | £14m | £14.7m | £17.8m | £13.9m |
| Profit after tax | £11m | £14.3m | £16m | £13.4m |
| Profit (best available) | £11m | £14.3m | £16m | £13.4m |
| Staff costs | £4.3m | £3.4m | £3.3m | £2.4m |
| Employees (average) | 102 | 93 | 74 | 47 |
| Ratios | ||||
| Profit margin | 13.4% | 17.9% | 19.1% | 17.7% |
| Gross margin | 30.8% | 28.1% | 29.4% | 27.6% |
| Revenue per employee | £805k | £854k | £1.1m | £1.6m |
| Profit per employee | £108k | £153k | £216k | £284k |
| Cash conversion | −78% | −40.9% | −21.1% | −198.9% |
| Growth (year on year) | ||||
| Revenue growth | — | ▼3.3% | ▲5.8% | ▼10.4% |
| Profit growth | — | ▲29.8% | ▲12.3% | ▼16.5% |
| Headcount growth | — | ▼8.8% | ▼20.4% | ▼36.5% |
| Balance sheet — indirect signals, not revenue | ||||
| Cash at bank | £2m | £5.7m | £1.4m | £100k |
| Net assets | £13.5m | £27.7m | £37.2m | £17.6m |
| Fixed assets | £4.6m | £4.4m | £6k | £402k |
| Current assets | £37.9m | £44.3m | £46.2m | £40.1m |
| Debtors | £19.1m | £16.5m | £17m | £15.4m |
| Deferred income | £3.6m | £5.1m | £5.5m | £3m |
| Cash from operations | −£10.9m | −£5.9m | −£3.7m | −£27.3m |
| Source | FullAccounts · bulk data Jul 2024 | FullAccounts · bulk data Jul 2024 | FullAccounts · bulk data Jul 2025 | FullAccounts · bulk data Aug 2026 |
How the business works
- Profit margin
- 17.7%
- Profit ÷ revenue.
- Gross margin
- 27.6%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £1.6m
- Revenue ÷ average employees.
- Profit per employee
- £284k
- Profit ÷ average employees.
- Cash conversion
- −198.9%
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- 0.5%
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- 4%
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- 20.4%
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- ▼53%
- Now £17.6m
- Cash at bank
- ▼93%
- Now £100k
- Headcount
- ▼36%
- Now 47
- Deferred income
- ▼46%
- Now £3m
- Fixed assets
- ▲6600%
- Now £402k
Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.
Similar profitable businesses
- Catalent CTS (Edinburgh) LimitedSwindon · Manufacture of pharmaceutical preparations
- Revenue
- £68.7m
- Profit
- £17.8m
- Staff
- 264
- Swedish Orphan Biovitrum LtdCambridge · Manufacture of pharmaceutical preparations
- Revenue
- £88.7m
- Profit
- £3.5m
- Staff
- 92
- Nicobrand LimitedCounty Londonderry · Manufacture of pharmaceutical preparations
- Revenue
- £62.5m
- Profit
- £19.9m
- Staff
- 88
- DR Reddy's Laboratories (UK) LimitedCambridge · Manufacture of pharmaceutical preparations
- Revenue
- £95m
- Profit
- £10.1m
- Staff
- 46
- Neon Healthcare LtdHertford · Manufacture of pharmaceutical preparations
- Revenue
- £51.2m
- Profit
- £1.7m
- Staff
- 21
- Dermal Laboratories LimitedLoughton · Manufacture of pharmaceutical preparations
- Revenue
- £45.7m
- Profit
- £2.4m
- Staff
- 171
Sources
Latest figures from FullAccounts for the year to 31 Dec 2025 (profit £13.4m), from the Companies House accounts bulk data published Aug 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.